Accurate Risk Assessment for the Development of PML in Natalizumab Treated MS Patients Requires CSF Analysis
Peggy Bettin, Jerry Lin, and Saud A. Sadiq. Presented at the 2012 annual meeting of the American Academy of Neurology, held April 23-27 in New Orleans, LA.